Tag Archive for: Novo

Novo Holdings posts record Total Income and Investment Returns of DKK 60 billion (€8.0 billion) in 2024, with the Investment Portfolio delivering above-benchmark returns, alongside strong growth at the Novo Group companies

/in

Copenhagen, Denmark – Novo Holdings today announced its financial results for 2024.* Record returns from the Investment Portfolio and growth of the Novo Group companies drive Total Income and Investment Returns to DKK 60 billion (€8.0 billion) for 2024, up from DKK 31 billion (€4.2 billion) in 2023. The Investment Portfolio generated a return of […]

Read more

QL Biopharm Presented Results from Phase 1c Clinical Study on its Novel Once-Monthly GLP-1RA ZT002 at EASD 2024

/in

– ZT002 was safe and well tolerated in both biweekly and monthly dosing arms in patients with overweight or obesity with a tolerability profile aligned with the GLP-1RA class – The open-label extension with ZT002 120 mg, once-monthly, showed 17.1% reduction in body weight at 30 weeks Beijing, China, 12 September 2024 – Beijing QL […]

Read more

Weekly wrap-up: Novo Holdings leads $105 million financing of Magenta Medical to support FDA approval for world’s smallest heart pump

/in

Novo Holdings, a leading life science investor, on Tuesday announced that it has led a $105 million financing in Magenta Medical, developer of the Elevate™ System, the world’s smallest heart pump. The financing will be used to advance the company’s US clinical programs in multiple mechanical circulatory support (MCS) indications and to secure the first […]

Read more

New innovative crops could significantly reduce agriculture’s climate change impact and environmental footprint

/in

The Novo Nordisk Foundation has awarded a grant of up to USD 21.1 million to CIMMYT for a groundbreaking initiative to mitigate the environmental impact of agriculture, by developing new wheat varieties that are capable of reducing agriculture’s nitrogen footprint. The CropSustaiN initiative could have sweeping implications for global food security and environmental sustainability. As […]

Read more

Novo Holdings Portfolio Company Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

/in

Deal value up to US$1.05 billion Novo Holdings co-led Series A financing in Amolyt, supported additional financings and is Amolyt’s largest investor Acquisition validates Novo Holdings’ strategy to identify and invest long term in high quality European biotech companies Copenhagen, Denmark – Novo Holdings A/S, a leading international life sciences investor, today announced that its portfolio […]

Read more